Related Experiment Video
Updated: May 27, 2026
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Prostaglandin E(2) potentiates methylmalonate-induced seizures.
Mirian Graciela Silva Stiebbe Salvadori1, Cristina Ruedell Reschke Banderó, Ana Cláudia Jesse
1Department of Physiology and Pharmacology, Center of Health Sciences, Federal University of Santa Maria, Santa Maria, RS, Brasil.
Epilepsia
|November 19, 2011
Summary
Prostaglandin E2 (PGE2) exacerbates seizures in methylmalonic acidemia (MMA) by activating cyclooxygenase-2 (COX-2). This highlights inflammation's role in MMA-related neurological issues.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Inflammation Research
Background:
- Methylmalonic acidemias (MMA) cause neurologic dysfunction, including seizures, often triggered by infections.
- Inflammation is implicated in seizure facilitation, but its role in MMA-induced seizures is unclear.
Purpose of the Study:
- To investigate the involvement of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) in methylmalonate (MMA)-induced seizures.
- To understand the inflammatory mechanisms underlying MMA-associated neurological complications.
Main Methods:
- Adult male Wistar rats underwent electroencephalography (EEG) recording.
- Animals received intracerebroventricular (i.c.v.) injections of PGE2 or saline, followed by MMA or NaCl.
- The anticonvulsant effects of celecoxib (a COX-2 inhibitor) were tested, and its interaction with PGE2 was examined.
Main Results:
- PGE2 reduced seizure latency and increased seizure amplitude in MMA-treated rats.
- Celecoxib (2 mg/kg) prevented MMA-induced seizures, but this effect was blocked by PGE2.
- Higher celecoxib doses (20 mg/kg) did not show a protective effect.
Conclusions:
- Prostaglandin E2 plays a significant role in mediating MMA-induced seizures.
- These findings support the hypothesis that inflammation exacerbates neurologic dysfunction in methylmalonic acidemia patients.
More Related Videos
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:14Alkylation of β-Diester Enolates: Malonic Ester Synthesis
Malonic ester synthesis is a method to obtain α substituted carboxylic acids from ꞵ-diesters such as diethyl malonate and alkyl halides.
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...